Immunohistochemical analysis using the ZEB1 antibody was performed (Figure 7(1A,1B)) on samples (n = 6) of benign and malignant tumors with good prognosis (benign mixed tumor and carcinoma in mixed tumor, grade 1) and on samples (n = 4) of malignant tumors with reserved prognosis (carcinoma in mixed tumor, grade 2; tubular carcinoma; and solid carcinoma, grade 3). Here, ZEB1 is linked to tubular adenocarcinoma.